newsfilter
← Latest News
Business Wire·

SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda SARS-CoV-2 Variants

FDA findings from research published in bioRxiv using in vitro pseudovirus models confirm SAB-185 broadly neutralizes variants of concern SAB-185 currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial SAB Biotherapeutics (SAB), a clin